Фокальная нодулярная гиперплазия печени как позднее осложнение, возникающее после аутологичной трансплантации гемопоэтических стволовых клеток у детей с нейробластомой (клинический случай и обзор литературы)

Фокальная нодулярная гиперплазия (ФНГ) – регенеративное объемное образование печени, которое может возникать как следствие реакции гепатоцитов на локальные сосудистые нарушения кровообращения и являться одним из поздних осложнений у больных, получивших высокодозную химиотерапию с последующей трансплантацией гемопоэтических стволовых клеток. В данной статье представлено описание 2 клинических случаев развития ФНГ печени у пациентов с нейробластомой группы высокого риска, выявленной на поздних сроках от окончания специфического лечения. Возможной причиной развития ФНГ печени у данных пациентов могло быть использование алкилирующих препаратов (ифосфамид, треосульфан, бусульфан, мелфалан).

1. Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010;362(23):2202–11. doi: 10.1056/NEJMra0804577.

2. Goodman M.S., Gurney J.G., Smith M.A., Olshan A.F. Sympathetic nervous system tumors. In: Ries L.A.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L. Jr, Bunin G.R., eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program. Bethesda, MD, 1999. Pp. 65–72.

3. Spix C., Pastore G., Sankila R., Stiller C.A., Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081–91. doi: 10.1016/j.ejca.2006.05.008.

4. Matthay K.K., Maris J.M., Schleiermacher G., Nakagawara A., Mackall C.L., Diller L., Weiss W.A. Neuroblastoma. Nat Rev Dis Primers 2016;2:16078. doi: 10.1038/nrdp.2016.78.

5. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165–73. doi: 10.1056/NEJM199910143411601.

6. Laino M.E., Monti S., Klimstra D.S., Tang L.H., Mannelli L. Treatment-related Focal Nodular Hyperplasia Mimicking Liver Metastases. J Pediatr Hematol Oncol 2019;41(2):138–9. doi: 10.1097/ MPH.0000000000001362.

7. Bouyn C.I., Leclere J., Raimondo G., Le Pointe H.D., Couanet D., Valteau-Couanet D., Hartmann O. Hepatic focal nodular hyperplasia in children previously treated for a solid tumor. Incidence, risk factors, and outcome. Cancer 2003;97:3107–13. doi: 10,1002/cncr.11452.

8. Kumagai H., Masuda T., Oikawa H., Endo K., Takano T. Focal nodular hyperplasia of the liver: direct evidence of circulatory disturbances. J Gastroenterol Hepatol 2000;15:1344–7. PMID: 11129233.

9. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22:983–93. PMID: 7657307.

10. Franchi-Abella S., Branchereau S. Benign hepatocellular tumors in children: focal nodular hyperplasia and hepatocellular adenoma. Int J Hepatol 2013; 2013:215064. doi: 10.1155/2013/215064.

11. Stocker J.T., Kamal G.I. Focal nodular hyperplasia of the liver: a study of 21 pediatric cases Cancer 1981;48(2):336–45. PMID: 7237404.

12. Pillon M., Carucci N.S., Mainardi C., Carraro E., Zuliani M., Chemello L., Calore E., Tumino M., Varotto S., Toffolutti T., Destro R., Gazzola M. V., Alaggio R., Basso G., Messina C. Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. Bone Marrow Transplant 2015;50(3):414–9. doi: 10.1038/bmt.2014.276.

13. Joyner B.L., Goyal R.K., Newman B., Levin T.L. Focal nodular hyperplasia of the liver: a sequela of tumor therapy. Pediatr Radiol 2005;35(12):1234–9. doi: 10.1007/s00247-005-1558-8.

14. Fan C.Q., Crawford J.M. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol 2014;4(4):332–46. doi: 10.1016/j.jceh.2014.10.002.

15. Masetti R., Colecchia A., Rondelli R., Martoni A., Vendemini F., Biagi C., Prete A., Festi D., Lima M., Pession A. Benign hepatic nodular lesions after treatment for childhood cancer. J Pediatr Gastroenterol Nutr 2013;56(2):151–5. doi: 10.1097/MPG.0b013e31826f7660.

16. Berthold F., Ernst A., Hero B., Klingebiel T., Kremens B., Schilling F. H., Simon T. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. Br J Cancer 2018;119(3):282–90. doi: 10.1038/s41416-018-0169-8.

17. Elzembely M.M., Dahlberg A.E., Pinto N., Leger K.J., Chow E.J., Park J.R., Carpenter P.A., Baker K.S. Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue. Pediatr Blood Cancer 2019;66(1):e27421. doi: 10.1002/pbc.27421.

18. Benz-Bohm G., Hero B., Gossmann A., Simon T., Körber F., Berthold F. Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? Eur J Radiol 2010;74(3):e1–5. doi: 10.1016/j.ejrad.2009.03.011.

19. Bartolotta T.V., Midiri M., Scialpi M., Sciarrino E., Galia M., Lagalla R. Focal nodular hyperplasia in normal and fatty liver: a qualitative and quantitative evaluation with contrast-enhanced ultrasound. Eur Radiol 2004;14:583–91. doi: 10.1007/s00330-003-2089-z.

20. Wang W., Chen L.D., Lu M.D., Liu G.J., Shen S.L., Xu Z.F., Xie X.Y., Wang Y., Zhou L.Y. Contrast-enchanced ultrasound features of histologically proven focal nodular hyperplasia: diagnostic performance compared with contrast-encanced CT. Eur Radiol 2013;23(9):2546–54. doi: 10.1007/s00330-013-2849-3.

21. Dill-Macky M.J., Burns P.N., Khalili K., Wilson S.R. Focal hepatic masses: enhancement patterns with SH U 508A and pulse-inversion US. Radiology 2002;222: 1:95–102. doi: 10.1148/radiol.2221010092.

22. Lencioni R., Cioni D., Bartolozzi C. Focal liver lesions, detection, characterization, ablation. Springer Verlag, 2005. ISBN: 3540644644.

23. Li A.-J., Zhou W.P., Wu M.C. Diagnosis and treatment of hepatic focal nodular hyperplasia: report of 114 cases. Zhonghua Wai Ke Za Zhi (Chinese J Surg) 2006;44(5):321–3. PMID: 16635391.

24. Mortele K.J., Praet M., Van Vlierberghe H., Kunnen M., Ros P.R. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. Am J Roentgenol 2000;175(3):687–92. doi: 10.2214/ajr.175.3.1750687.

25. Seale M.K., Catalano O.A., Saini S., Hahn P.F., Sahani D.V. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics: a review publication of the Radiological Society of North America 2009;29(6):1725–48. doi: 10.1148/rg.296095515.

26. Sharp S.E., Trout A.T., Weiss B.D., Gelfand M.J. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics 2016;36(1):258–78. doi: 10.1148/rg.2016150099.

27. Vik T.A., Pfluger T., Kadota R., Castel V., Tulchinsky M., Farto J.C., Heiba S., Serafini A., Tumeh S., Khutoryansky N., Jacobson A.F. (123) I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009;52(7):784–90. doi: 10.1002/pbc.21932.

28. Nakajo M., Shapiro B., Copp J., Kalff V., Gross M.D., Sisson J.C., Beierwaltes W.H. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131] iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983;24(8):672–82. PMID: 6135764.

29. Jacobsson H., Hellström P.M., Kogner P., Larsson S.A. Different concentrations of I-123 MIBG and In-111 pentetreotide in the two main liver lobes in children: persisting regional functional differences after birth? Clin Nucl Med 2007;32(1):24–8. doi: 10.1097/01.rlu.0000249592.95945.e4.

30. Kulatunge C.R., Son H. False-positive 123I-MIBG scintigraphy due to multiple focal nodular hyperplasia. Clin Nucl Med 2013;38(12):976–8. doi: 10.1097 / RLU.0000000000000234.